Leadership & ownership

Our leadership team and ownership structure

ester baiget smiling

Novo Holdings A/S is the holding company for companies in the Novo Group, with an ownership stake in Novozymes A/S. Our leadership and governance structure promotes transparent and sustainable corporate value creation.

Management 

Management in Novozymes A/S is headed by Novozymes' Board of Directors and the Executive Leadership Team.

Our ten-member Board of Directors and eight-member Executive Leadership Team comprise broad and global management experience, comprehensive biotech expertise and in-depth knowledge of Novozymes' business.

The members' competencies combine to ensure the best possible management of the company.

Board of Directors

Cees de Jong

Kim Stratton

Heine Dalsgaard

Sharon James

Kasim Kutay

Morten Sommer

Anne Breum

Anders Hentze Knudsen

Preben Nielsen

Jens Øbro

Executive Leadership Team

Novozymes has combined with Chr. Hansen to become Novonesis, a global biosolutions company.

Information about our Executive Leadership Team are available on novonesis.com.

Ownership

Novozymes’ stock consists of two types: A and B shares. Both shares have a nominal value of DKK 2 per share, but an A share carries 10 times as many votes as a B share.

Novozymes had more than 60,000 shareholders at the end of 2022, and 76% of the B shares were held outside Denmark, mainly by institutional investors. Fifty institutional investors, including Novo Holdings A/S, held approximately 60% of the B shares. Novo Holdings A/S held 25.6% of the total common stock in Novozymes and controlled 72.7% of the votes.

The Novo Nordisk Foundation wishes to be an “Engaged Owner” in relation to Novozymes and apply engaged ownership objectives and principles which among other things are described in ‘Objectives & Principles for engaged ownership in relation to Novo Nordisk A/S and Novozymes A/S’, cf. www.novonordiskfonden.com. The Novo Nordisk Foundation supports Novozymes in achieving its vision, ensuring competitive financial results and adhering to the Charter for Companies in the Novo Group. All strategic and operational matters are solely decided by the Board and the Executive Management of Novozymes.

Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner

For legal reasons, the announcement and all related material to the announcement can only be found on a dedicated microsite.

Sunrise over forest